CPT 501T — Analysis Of Data From CT Study Of Heart Blood Vessels To Assess Severity Of Heart Artery Disease, With Interpretation And Report (1 hospital, — samples)
CPT 501U — Oncology (colorectal), blood, quantitative measurement of cell-free DNA (cfDNA) (12 hospitals, — samples)
CPT 502T — HC Coronary Ffr Data Prep Transm (4 hospitals, — samples)
CPT 502U — Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV (12 hospitals, — samples)
CPT 503T — HC Coronary Ffr From Cta Data Mod (4 hospitals, — samples)
CPT 503U — Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/np-tau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorith (12 hospitals, — samples)
CPT 504T — Analysis Of Data From CT Study Of Heart Blood Vessels To Assess Severity Of Heart Artery Disease, Anatomical Data Review (1 hospital, — samples)
CPT 504U — Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism (12 hospitals, — samples)
CPT 505U — Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism (12 hospitals, — samples)
CPT 506T — MAC PGMT OPT DNS MEAS HFP (12 hospitals, — samples)
CPT 506U — Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus (12 hospitals, — samples)
CPT 507U — Oncology (ovarian), DNA, whole-genome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected (12 hospitals, — samples)
CPT 508T — Ultrasound Measurement Of Bone Density In Shin Bone (1 hospital, — samples)
CPT 508U — Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection (12 hospitals, — samples)
CPT 509U — Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection (12 hospitals, — samples)
CPT 50U — TRGT GEN SEQ DNA 194 GENES (12 hospitals, — samples)
CPT 511U — Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug (12 hospitals, — samples)
CPT 512U — Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of M (12 hospitals, — samples)
CPT 513U — Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin-fixed paraffin-embedded (FFPE) tissue, repor (12 hospitals, — samples)
CPT 514T — Visual Axis Identification Using Patient Fixation During Operation (1 hospital, — samples)
CPT 514U — Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL) (12 hospitals, — samples)
CPT 515U — Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL) (12 hospitals, — samples)
CPT 516U — Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status (12 hospitals, — samples)
CPT 517U — Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications (12 hospitals, — samples)
CPT 518U — Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications (12 hospitals, — samples)
CPT 519U — Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LC-MS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medication (12 hospitals, — samples)
CPT 520U — Therapeutic drug monitoring, 200 or more drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications (12 hospitals, — samples)
CPT 521T — INTERROG DEV EVAL WCS IP (12 hospitals, — samples)
CPT 521U — Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood (12 hospitals, — samples)
CPT 52284 — CYSTOURETHROSCOPY, WITH MECHANICAL URETHRAL DILATION AND URETHRAL THERAPEUTIC DRUG DELIVERY BY DRUG-COATED BALLOON CATHETER FOR URETHRAL STRICTURE OR STENOSIS, MALE, INCLUDING FLUOROSCOPY, WHEN PERFORMED (10 hospitals, — samples)
CPT 522T — PRGRMG DEV EVAL WCS IP (12 hospitals, — samples)
CPT 522U — Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiqualitative, blood (12 hospitals, — samples)
CPT 523U — Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single-nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location (12 hospitals, — samples)